No benefit of additional treatment with exenatide in patients with an acute myocardial infarction
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: This double blinded, placebo controlled randomized clinical trial studies the effect of exenatide on myocardial infarct size. The glucagon-like peptide-1 receptor agonist exenatide has possible cardioprotective properties during reperfusion after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. METHODS: 191 patients were randomly assigned to intravenous exenatide or placebo initiated prior to percutaneous coronary intervention using 10μg/h for 30min followed by 0.84μg/h for 72h. Patients with a previous myocardial infarction, Trombolysis in Myocardial Infarction flow 2 or 3, multi-vessel disease, or diabetes were excluded. Magnetic resonance imaging (MRI) was performed to determine infarct size, area at risk (AAR) (using T2-weighted hyperintensity (T2W) and late enhancement endocardial surface area (ESA)). The primary endpoint was of 4-month final infarct size, corrected for the AAR measured in the acute phase using MRI. RESULTS: After exclusion, 91 patients (age 57.4±10.1years, 76% male) completed the protocol. There were no baseline differences between groups. No difference was found in infarct size corrected for the AAR in the exenatide group compared to the placebo group (37.1±18.8 vs. 39.3±20.1%, p=0.662). There was also no difference in infarct size (18.8±13.2 vs. 18.8±11.3% of left ventricular mass, p=0.965). No major adverse cardiac events occurred during the in-hospital phase. CONCLUSION: Exenatide did not reduce myocardial infarct size expressed as a percentage of AAR in ST elevated myocardial infarction patients successfully treated with percutaneous coronary intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yellon, D. M., & Hausenloy, D. J. (2007) · New England Journal of Medicine · doi:10.1056/nejmra071667 · Cited by 3,797
We can do better―improving the health of the American people
Schroeder, S. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmsa073350 · Cited by 1,065
Nikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000120505.91348.58 · Cited by 901 · cited 5×
“The maintenance dose and duration were based on results of our previous preclinical study [11] and a clinical study with GLP-1 [7], in order to achieve a potential beneficial effect on metabolic efficiency and cardiac function.”
Influential
Cited by
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
Ussher, J. R., & Drucker, D. J. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00849-3 · Cited by 577
Hausenloy, D. J., Garcia-Dorado, D., Bøtker, H. E., Davidson, S. M., Downey, J., Engel, F. B., Jennings, R., Lecour, S., Leor, J., Madonna, R., et al. (2017) · Cardiovascular Research · doi:10.1093/cvr/cvx049 · Cited by 356
Ischaemic conditioning and targeting reperfusion injury: a 30 year voyage of discovery
Hausenloy, D. J., Barrabes, J. A., Bøtker, H. E., Davidson, S. M., Di Lisa, F., Downey, J., Engstrom, T., Ferdinandy, P., Carbrera-Fuentes, H. A., Heusch, G., et al. (2016) · Basic Research in Cardiology · doi:10.1007/s00395-016-0588-8 · Cited by 308
Konijnenberg, L. S. F., Damman, P., Duncker, D. J., Kloner, R. A., Nijveldt, R., van Geuns, R.-J. M., Berry, C., Riksen, N. P., Escaned, J., & van Royen, N. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvz301 · Cited by 261
Self-citationHeuvelman, V. D., Van Raalte, D. H., & Smits, M. M. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvz323 · Cited by 106
Metadata
- Authors
- Roos, S. T., Timmers, L., Biesbroek, P. S., Nijveldt, R., Kamp, O., van Rossum, A. C., van Hout, G. P. J., Stella, P. R., Doevendans, P. A., Knaapen, P., Velthuis, B. K., van Royen, N., Voskuil, M., Nap, A., & Appelman, Y.
- Venue
- International Journal of Cardiology
- Publisher
- Elsevier BV
- Published
- 2016-10
- Volume
- 220
- Pages
- 809-814
- ISSN
- 0167-5273 (ISSN-L)
- OpenAlex
- W2471875743
- Cited by
- 52
- References
- 3
- FWCI
- 4.69
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: No benefit of additional treatment with exenatide in patients with an acute myocardial infarction. https://app.cochat.ai/papers/10.1016/j.ijcard.2016.06.283
- The paper
- Roos, S. T., Timmers, L., Biesbroek, P. S., Nijveldt, R., Kamp, O., van Rossum, A. C., van Hout, G. P. J., Stella, P. R., Doevendans, P. A., Knaapen, P., Velthuis, B. K., van Royen, N., Voskuil, M., Nap, A., & Appelman, Y. (2016). No benefit of additional treatment with exenatide in patients with an acute myocardial infarction. International Journal of Cardiology. https://doi.org/10.1016/j.ijcard.2016.06.283
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.